Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-α36

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1485-1493

  Kang, Lianguo ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; ER 36; ICI 182,780; MAPK; Oestrogen receptor; PEITC

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; FULVESTRANT; ISOTHIOCYANIC ACID DERIVATIVE; LEUPEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENETHYL ISOTHIOCYANATE;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENOME, HUMAN; HUMANS; ISOTHIOCYANATES; LEUPEPTINS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 77955126128     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00877.x     Document Type: Article

References (35)

1. Cancer facts & figures 2008 2008, American Cancer Society, Atlanta, Georgia: American Cancer Society
2. Cheung KL, Owers R, Robertson JF. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Endocr Relat Cancer. 2006, 13:251-5.
3. Wakeling AE, Dukes M, Bowler J. A potent specific pure antioestrogen with clinical potential. Cancer Res. 1991, 51:3867-73.
4. Robertson JFR, Nicholson RI, Anderson E. The antitumor effects of single dose, long acting Faslodex™ (ICI 182780) compared with tamoxifen in post-menopausal primary breast cancer patients treated before surgery. Breast Cancer Res Treat 2000, 59:99.
5. Perey L, Paridaens R, Hawle H. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2007, 18:64-9.
6. Howell A, Robertson JF, Quaresma Albano J. Fulvestrant, formerly ICI 182780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002, 20:3396-403.
7. Wang Z, Zhang X, Shen P. A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA. 2006, 103:9063-68.
8. Wang Z, Zhang X, Shen P. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005, 336:1023-7.
9. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992, 18:1-29.
10. Verhoeven DT, Goldbohm RA, van Poppel G. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiology Biomarkers Prev. 1996, 5:733-48.
11. Xiao D, Vogel V, Singh SV. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol Cancer Ther. 2006, 5:2931-45.
12. Tang L, Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol Cancer Ther. 2005, 4:1250-9.
13. Fowke JH, Chung FL, Jin F. Urinary isothiocyanate levels, Brassica, and human breast cancer. Cancer Res. 2003, 63:3980-6.
14. Ambrosone CB, McCann SE, Freudenheim JL. Breast Cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004, 134:1134-8.
15. Fenwick GR, Heaney RK, Mullin WJ. Glucosinolates and their breakdown products in food and food plants. Crit Rev Food Sci Nutr. 1983, 18:123-201.
16. Getahun SM, Chung FL. Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. Cancer Epidemiol Biomark Prev. 1999, 8:447-51.
17. Xiao D, Srivastava SK, Lew KL. Allyl isothiocyanate, a constituent of cruciferous vegetables inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 2003, 24:891-7.
18. Hu R, Kim BR, Chen C. The role of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cell. Carcinogenesis. 2003, 24:1361-7.
19. Srivastava SK, Singh SV. Cell cycle arrest and apoptosis-induced by benzyl isothiocyanate are associated with inhibition of nuclear factor kappa B activation in human pancreatic cancer cells. Carcinogenesis. 2004, 25:1701-9.
20. Tang L, Zhang Y. Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. J Nutr. 2004, 134:2004-10.
21. Tseng E, Scott-Ramsay EA, Morris ME. Dietary organic isothiocyanates are cytotoxic in human breast cancer MCF-7 and Mammary epithelial MCF-12A cell lines. Exp Biol Med. 2004, 229:835-42.
22. Kang L, Ding L, Wang ZY. Isothiocyanates repress estrogen receptor alpha expression in breast cancer cells. Oncol Rep. 2009, 21:185-92.
23. Preisler-Mashek MT, Solodin N, Stark BL. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am J Physiol Endocrinol Metab. 2002, 282:E891-8.
24. Nicholson RI, Gee JM, Manning DL. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann NY Acad Sci. 1995, 761:148-63.
25. Lee LM, Cao J, Deng H. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008, 28:479-83.
26. Nethrapalli IS, Tinnikov AA, Krishnan V. Estrogen activates mitogen-activated protein kinase in native, nontransfected CHO-K1, COS-7, and RAT2 fibroblast cell lines. Endocrinology. 2005, 146:56-63.
27. Zou Y, Ding L, Coleman M. Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett. 2009, 583:1368-74.
28. Mahfoudi A, Roulet E, Dauvois S. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Nat Acad Sci USA. 1995, 92:4206-10.
29. Montano MM, Ekena K, Krueger KD. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol. 1996, 10:230-42.
30. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem. 2003, 278:7630-8.
31. Wang LG, Liu XM, Chiao JW. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 2006, 27:2124-32.
32. deGraffenried LA, Hopp TA, Valente AJ. Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat. 2004, 85:111-20.
33. Wijayaratne AL, McDonnell D P. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 2001, 276:35684-92.
34. Ji Y, Morris ME. Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. Anal Biochem. 2003, 323:39-47.
35. Liebes L, Conaway CC, Hochster H. High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem. 2001, 291:279-89.